35 results
424B5
AUTL
Autolus Therapeutics plc
19 Aug 21
Prospectus supplement for primary offering
4:13pm
the right itself. The complaint must:
state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains … or that the plaintiff’s shares thereafter devolved on the plaintiff by operation of law; and
allege with particularity the efforts made by the plaintiff
424B5
AUTL
Autolus Therapeutics plc
24 Jul 19
Prospectus supplement for primary offering
4:20pm
to enforce the right itself. The complaint must:
state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff … complains or that the plaintiff’s shares thereafter devolved on the plaintiff by operation of law; and
allege with particularity the efforts made
S-3ASR
AUTL
Autolus Therapeutics plc
7 Feb 24
Automatic shelf registration
10:00pm
if the corporation fails to enforce the right itself. The complaint must:
state that the plaintiff was a stockholder at the time of the transaction of which … the plaintiff complains or that the plaintiff’s shares thereafter devolved on the plaintiff by operation of law; and
allege with particularity
F-3
AUTL
Autolus Therapeutics plc
17 Jul 19
Shelf registration (foreign)
5:15pm
the right itself. The complaint must:
state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains … or that the plaintiff’s shares thereafter devolved on the plaintiff by operation of law; and
allege with particularity the efforts made by the plaintiff
F-3
AUTL
Autolus Therapeutics plc
6 Aug 21
Shelf registration (foreign)
2:30pm
:
state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiff’s shares thereafter … devolved on the plaintiff by operation of law; and
allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff
424B5
s5ymyk64
18 Sep 20
Prospectus supplement for primary offering
8:01am
424B5
b0tfvhk1
9 Feb 24
Prospectus supplement for primary offering
5:15pm
424B5
lbkvllv wtc8jn50
22 Jan 20
Prospectus supplement for primary offering
5:30pm
424B5
psm9tg3 cwm
8 Dec 22
Prospectus supplement for primary offering
4:10pm
424B5
idd 22nymf967zs8sn
8 Feb 21
Prospectus supplement for primary offering
5:27pm
424B5
7u0ny8wkjq 1b0jct9x
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
kw7pno
11 Feb 21
Prospectus supplement for primary offering
5:16pm
F-1
p27pbz
8 Apr 19
Registration statement (foreign)
4:34pm
DRS
t2ck 196ru6nrq
23 Nov 18
Draft registration statement
12:00am
424B5
8h6kltsxlybs
24 Jan 20
Prospectus supplement for primary offering
4:11pm
424B4
yrhqm3q
11 Apr 19
Prospectus supplement with pricing info
4:10pm
20-F
EX-2.3
pm8u3 5x59j
23 Nov 18
Annual report (foreign)
12:00am
8-K
EX-10.2
d7pfq
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
6-K
EX-99.2
gjl valbcg
8 Nov 21
Securities Purchase Agreement
5:28pm
8-K
EX-10.1
fgqrpj2
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am